Dania Saltagi, PA
Medical · Noblesville, INNPI 1922595966
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 406 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 406 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Sanofi$775
- Takeda Pharmaceuticals U.S.A., Inc.$458
- Jazz Pharmaceuticals Inc.$386
- Boehringer Ingelheim$315
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,11199%
- Education$791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,137 |
| GSK | 98 | $1,048 |
| Sanofi | 45 | $775 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $458 |
| Jazz Pharmaceuticals Inc. | 16 | $386 |
| Boehringer Ingelheim | 13 | $315 |
| Insmed, Inc. | 16 | $272 |
| Grifols USA, LLC | 11 | $265 |
| AbbVie | 11 | $249 |
| Mylan Specialty L.p. | 11 | $173 |
| Paratek Pharmaceuticals, Inc. | 10 | $173 |
| United Therapeutics Corporation | 7 | $161 |
| Teva Pharmaceuticals USA, Inc. | 9 | $153 |
| Amgen | 6 | $130 |
| Actelion Pharmaceuticals US, Inc. | 6 | $129 |
| Regeneron Healthcare Solutions, Inc. | 5 | $109 |
| E.r. Squibb & Sons, L.L.C. | 6 | $109 |
| Johnson & Johnson | 7 | $107 |
| Pfizer | 5 | $101 |
| Viatris Specialty LLC | 4 | $85 |
| Baxter Healthcare | 3 | $85 |
| Philips North America LLC | 5 | $82 |
| Sanofi-aventis U.S. LLC | 2 | $75 |
| Verona Pharma, Inc. | 4 | $75 |
| Lilly USA, LLC | 3 | $64 |
| Gilead | 3 | $58 |
| Novartis | 3 | $56 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $55 |
| Pulmonx Corporation | 3 | $51 |
| Fisher & Paykel Healthcare Inc | 2 | $46 |
| Genentech USA, Inc. | 5 | $36 |
| Resmed Corp | 2 | $34 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Itamar Medical Inc | 1 | $31 |
| Merck | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Bayer | 1 | $18 |
| Chiesi USA, Inc. | 1 | $16 |
How this compares
$7,190 in reported general payments places this provider in the 90th percentile of 273 medical providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 150 | $119,067 |
| Dupixent PenDupilumab | 24 | $98,030 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $22,955 |
| XifaxanRifaximin | 12 | $22,351 |
| Spiriva RespimatTiotropium Bromide | 23 | $14,588 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,467 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $7,423 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,436 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $4,274 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $3,010 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $1,766 |
| Doxycycline Hyclate | 36 | $222 |
| Prednisone | 62 | $183 |
| Montelukast Sodium | 20 | $109 |
| CefuroximeCefuroxime Axetil | 11 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,048 | $128,534167 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,137 | $28,39251 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $315 | $22,01038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 273 medical providers in Indiana.
Other medical in Noblesville
- Corrine MillerNoblesville$2K
- Meggie BeckleyIndianapolis$125K
- Jennifer ConnerIndianapolis$98K
- Brandon BoydCarmel$46K
- Karey DavisNew Castle$45K
- Sheryl NewCarmel$39K
- Lindsey GradyValparaiso$39K
- Jennifer IrwinIndianapolis$34K
- Dennae DaltonZionsville$33K
- Jenifer FortneyFort Wayne$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.